Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 133 | 32 | 99 |
| Samples | 127 | 29 | 96 |
| Peptides | 92 | 18 | 75 |
Function
NR0B2 · Nuclear receptor subfamily 0 group B member 2
The protein encoded by this gene is an unusual orphan receptor that contains a putative ligand-binding domain but lacks a conventional DNA-binding domain. The gene product is a member of the nuclear hormone receptor family, a group of transcription factors regulated by small hydrophobic hormones, a subset of which do not have known ligands and are referred to as orphan nuclear receptors. The protein has been shown to interact with retinoid and thyroid hormone receptors, inhibiting their ligand-dependent transcriptional activation. In addition, interaction with estrogen receptors has been demonstrated, leading to inhibition of function. Studies suggest that the protein represses nuclear hormone receptor-mediated transactivation via two separate steps: competition with coactivators and the direct effects of its transcriptional repressor function. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000254227 | Q15466 | 133 | 92 |
Gene Properties
Recurrent Mutations
All 92 amino-acid changes on canonical ENST00000254227 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NR0B2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NR0B2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Rhabdomyosarcoma | 0/33 0% | 3/171 2% |
| Endometrial Carcinoma | 1/42 2% | 5/612 1% |
| Melanoma | 0/210 0% | 15/1899 1% |
| Gastric Carcinoma | 4/74 5% | 8/1809 0% |
| Colorectal Carcinoma | 3/143 2% | 14/3239 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 3/810 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Other Solid Cancers | 0/94 0% | 7/1515 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Glioma | 1/52 2% | 7/2127 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 4/1390 0% |
| Non-Cancerous | 1/104 1% | 2/830 0% |
| Bladder Carcinoma | 1/58 2% | 2/956 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Hepatocellular Carcinoma | 0/46 0% | 6/2210 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Breast Carcinoma | 3/144 2% | 4/3264 0% |
| Neuroblastoma | 1/87 1% | 1/1331 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 2/2640 0% |
| Biliary Tract Carcinoma | 1/54 2% | 0/950 0% |
| Prostate Carcinoma | 2/13 15% | 0/2105 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 2/2550 0% |
| Other Blood Cancers | 0/61 0% | 2/2725 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 1/1592 0% |
| Head and Neck Carcinoma | 0/85 0% | 1/1574 0% |
Mutation Distribution
Where NR0B2 is mutated · all tissues, split by cell line vs tissue
How many mutations in NR0B2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 34 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 133 mutations in NR0B2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|